Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company
will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00
a.m.–10:30 a.m. ET in New York, NY.
The event will feature presentations from Seres management and leading
academic subject matter experts on the microbiome as a new therapeutic
target, with a focus on the Seres pipeline and the opportunity for
– Preclinical data provide mechanistic insights related to the
potency of microbiome therapeutics to augment immuno-oncology
treatments; initiation of clinical study in metastatic melanoma planned
for later this year –
– FDA dialogue ongoing to support development of SER-287 for
Ulcerative Colitis; Company plans to initiate clinical trial in mid-2018
– Company to host Microbiome R&D Day on May 24 in New York City –
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 7, 2018--
Therapeutics, Inc. (NASDAQ:MCRB) today announced that management
will host a conference call and live audio webcast on May 9, 2018 at
8:30 a.m. ET to discuss first quarter 2018 financial results and provide
a general business update.
To access the conference call, please dial 844-277-9450 (domestic) or
336-525-7139 (international) and reference the conference ID number